In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
656: Ralph Nader Reflects On His Auto Safety Campaign, 55 Years Later
654: What’s That Smell? An AI Nose Knows
655: Jane Goodall On Life Among Chimpanzees
654: The ‘Wet-Dog Shake’ And Other Physics Mysteries
657: Ig Nobel Prizes | Stop Flushing Your Health Data Down The Toilet
653: The West’s Wild Horses | Artist Explores History Of Humans Genetically Modifying Pigs
650: Moon Rock Research | Science of Unraveling Sweaters
652: 2023’s Best Science Books For Kids
649: How AI Chatbots Can Reinforce Racial Bias In Medicine
651: An Exoplanet Where It Rains Sand
648: Ask A Chef: How Can I Use Science To Make Thanksgiving Tastier?
645: Monumental And Invisible: How Infrastructure Works
647: Everything You Never Knew About Squash And Pumpkins
644: How A University Is Adjusting One Year After ChatGPT
646: Euclid Telescope’s First Images | A Black Hole That Came From Gas
642: How Five Elements Define Life On Earth
639: Climate Future Exhibit | Oregon's Proposed Fish Vacuum
641: How A Deaf Advisory Group Is Changing Healthcare
643: 40 Years Of Sounding The Alarm On Nuclear Winter
640: CRISPR-Based Sickle Cell Treatment | Pain Tolerance From Neanderthals
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL